271
Views
3
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis

, , , &
Pages 267-275 | Published online: 29 Apr 2019

References

  • Gary G. Optimizing treatment approaches in seborrheic dermatitis. J Clin Aesthet Dermatol. 2013;6(2):44.
  • Gupta A, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18(1):13–26. doi:10.1111/jdv.2004.18.issue-114678527
  • Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome: a clinicopathologic study. J Am Acad Dermatol. 1986;14(2):242–248.2936776
  • Burton J, Pye R. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed). 1983;286(6372):1169–1170.
  • Pechère M, Krischer J, Remondat C, Bertrand C, Trellu L, Saurat JH. Malassezia spp carriage in patients with seborrheic dermatitis. J Dermatol. 1999;26(9):558–561.10535248
  • Falk MHS, Linder MT, Johansson C, et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol. 2005;85(1):17–23. doi:10.1080/0001555041002227615848985
  • Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G. Seborrhoeic dermatitis and pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144(3):549–556.11260013
  • Riciputo R, Oliveri S, Micali G, Sapuppo A. Phospholipase activity in Malassezia furfur pathogenic strains: phospholipase‐Aktivität an patientenisolaten von Malassezia furfur. Mycoses. 1996;39(5‐6):233–235.8909036
  • Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest dermatol. 2001;116(5):769–773. doi:10.1046/j.1523-1747.2001.01321.x11348468
  • Ballanger F, Tenaud I, Volteau C, Khammari A, Dréno B. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res. 2008;300(5):215. doi:10.1007/s00403-007-0806-118330588
  • Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;(5):CD009446.
  • Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments:: facts and controversies. Clin Dermatol. 2013;31(4):343–351. doi:10.1016/j.clindermatol.2013.01.00123806151
  • Soares RC, Zani MB, Arruda ACBB, de Arruda LHF, Paulino LC. Malassezia intra-specific diversity and potentially new species in the skin microbiota from Brazilian healthy subjects and seborrheic dermatitis patients. PLoS One. 2015;10(2):e0117921. doi:10.1371/journal.pone.011792125695430
  • Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a cochrane review. JAMA dermatol. 2015;151(2):221–222. doi:10.1001/jamadermatol.2014.318625629391
  • Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005;141(1):47–52. doi:10.1001/archderm.141.1.4715655141
  • Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38. doi:10.1056/NEJMoa04200015635110
  • Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99(1):95–112. doi:10.1016/S0163-7258(03)00055-X12804701
  • Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol. 2010;49(11):1235–1243. doi:10.1111/j.1365-4632.2010.04579.x20964647
  • Bergman PW, Björkhem-Bergman L. Is there a role for statins in fungal infections? Expert Rev Anti Infect Ther. 2013;11(12):1391–1400. doi:10.1586/14787210.2014.85675524215244
  • Khurana S, Gupta S, Bhalla H, Nandwani S, Gupta V. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J Pharmacol Pharmacother. 2015;6(3):130. doi:10.4103/0976-500X.16201126311995
  • Toker S, Gulcan E, Caycı MK, Olgun EG, Erbilen E, Özay Y. Topical atorvastatin in the treatment of diabetic wounds. Am J Med Sci. 2009;338(3):201–204. doi:10.1097/MAJ.0b013e3181aaf20919667969
  • Buechner SA. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 2014;25(3):226–231. doi:10.3109/09546634.2013.78209223557492
  • Goldust M, Rezaee E, Raghifar R. Treatment of seborrheic dermatitis: comparison of sertaconazole 2% cream versus pimecrolimus 1% cream. Ir J Med Sci. 2013;182(4):703–706. doi:10.1007/s11845-013-0960-823715821
  • Hay R. Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol. 2011;165:2–8. doi:10.1111/j.1365-2133.2011.10570.x
  • McGinley KJ, Leyden JJ, Marples RR, Path M, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. 1975;64(6):401–405.237965
  • Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol. 1990;23(1):82–86.1694869
  • Bergbrant IM, Johansson S, Robbins D, Scheynius A, Faergemann J, Söderström T. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol. 1991;16(5):331–338.1838969
  • Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–1530.22364136
  • Naseri M, Hadipour A, Sepaskhah M, Namazi M. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med. 2010;19(1):58–61.20232758
  • Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Hemami MR. Atorvastatin for the treatment of plaque‐type psoriasis. Pharmacotherapy. 2011;31(11):1045–1050. doi:10.1592/phco.31.11.104522026392
  • Jacobi T, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol. 2003;149(6):1305–1306.14674922
  • Lanham M, Lebovic D, Domino S. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynecol Obstet. 2006;95(3):236–241. doi:10.1016/j.ijgo.2006.08.004
  • Ahmadvand A, Yazdanfar A, Yasrebifar F, Mohammadi Y, Mahjub R, Mehrpooya M. Evaluating the effects of oral and topical simvastatin in the treatment of acne vulgaris: a double-blind, randomized, placebo-controlled clinical trial. Curr Clin Pharmacol. 2018;13(4):279–283. doi:10.2174/157488471366618082114354530129417
  • Bracht L, Caparroz‐Assef SM, Magon T, Ritter AMV, Cuman RKN, Bersani‐Amado CA. Topical anti‐inflammatory effect of hypocholesterolaemic drugs. J Pharm Pharmacol. 2011;63(7):971–975. doi:10.1111/j.2042-7158.2011.01302.x21635264
  • Joshi R, Olver I, Keefe D, Marafioti T, Smith K. A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Support Care Cancer. 2007;15(9):1109–1112. doi:10.1007/s00520-007-0267-217516093
  • Otuki MF, Pietrovski EF, Cabrini DA. Topical simvastatin: preclinical evidence for a treatment of skin inflammatory conditions. J Dermatol Sci. 2006;44(1):45–47. doi:10.1016/j.jdermsci.2006.04.00616759838
  • Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17–24. doi:10.1111/j.1468-3083.2006.01838.x17207162
  • Cabral ME, Figueroa LI, Fariña JI. Synergistic antifungal activity of statin–azole associations as witnessed by Saccharomyces cerevisiae-and Candida utilis-bioassays and ergosterol quantification. Rev Iberoam Micol. 2013;30(1):31–38. doi:10.1016/j.riam.2012.09.00623069981
  • Galgóczy L, Lukács G, Nyilasi I, Papp T, Vágvölgyi C. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. Acta Biol Hung. 2010;61(3):356–365. doi:10.1556/ABiol.61.2010.3.1120724281